AZNAstraZenecaSigning up patients
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 600 (planned)
- Started
- Mar 27, 2025
- Main results expected
- Jan 19, 2029
- Fully finished
- Feb 19, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS), as assessed by BICR
Measured over: Until progression or death due to any cause (assessed up to approximately 45 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06989112 · record last updated 2026-10-13 · checked 2026-11-09 15:47 UTC